KRMD vs ATRC vs INFU vs LMAT vs BDX

For growth investors, KORU Medical Systems, Inc.

(KRMD) is the stronger pick with 22. 2% revenue growth year-over-year, versus 6. 4% for InfuSystem Holdings, Inc. (INFU). Becton, Dickinson and Company (BDX) offers the better valuation at 26. 3x trailing P/E (12. 3x forward), making it the more compelling value choice. Analysts rate KORU Medical Systems, Inc. (KRMD) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Becton, Dickinson and Company (BDX) is the cheapest at 26.

3x versus LeMaitre Vascular, Inc. at 42. 8x. On forward P/E, Becton, Dickinson and Company is actually cheaper at 12. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Becton, Dickinson and Company wins at 0. 74x versus LeMaitre Vascular, Inc. 's 1. 92x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, LeMaitre Vascular, Inc.

(LMAT) delivered a total return of +118. 2%, compared to -64. 2% for AtriCure, Inc. (ATRC). Over 10 years, the gap is even starker: KRMD returned +1116% versus BDX's +80. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), LeMaitre Vascular, Inc.

(LMAT) is the lower-risk stock at 0. 57β versus InfuSystem Holdings, Inc. 's 1. 50β — meaning INFU is approximately 162% more volatile than LMAT relative to the S&P 500. On balance sheet safety, InfuSystem Holdings, Inc. (INFU) carries a lower debt/equity ratio of 6% versus 76% for Becton, Dickinson and Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), KORU Medical Systems, Inc.

(KRMD) is pulling ahead at 22. 2% versus 6. 4% for InfuSystem Holdings, Inc. (INFU). On earnings-per-share growth, the picture is similar: InfuSystem Holdings, Inc. grew EPS 181. 8% year-over-year, compared to -0. 5% for Becton, Dickinson and Company. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

LeMaitre Vascular, Inc.

(LMAT) is the more profitable company, earning 23. 1% net margin versus -6. 4% for KORU Medical Systems, Inc. — meaning it keeps 23. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LMAT leads at 27. 2% versus -7. 2% for KRMD. At the gross margin level — before operating expenses — ATRC leads at 74. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Becton, Dickinson and Company (BDX) is the more undervalued stock at a PEG of 0. 74x versus LeMaitre Vascular, Inc. 's 1. 92x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Becton, Dickinson and Company (BDX) trades at 12. 3x forward P/E versus 370. 7x for AtriCure, Inc. — 358. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 82. 3% to $50. 67.

In this comparison, BDX (2.

7% yield), LMAT (0. 7% yield) pay a dividend. KRMD, ATRC, INFU do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, LeMaitre Vascular, Inc.

(LMAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 57), 0. 7% yield, +608. 6% 10Y return). InfuSystem Holdings, Inc. (INFU) carries a higher beta of 1. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LMAT: +608. 6%, INFU: +159. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KRMD is a small-cap high-growth stock; ATRC is a small-cap quality compounder stock; INFU is a small-cap quality compounder stock; LMAT is a small-cap quality compounder stock; BDX is a mid-cap quality compounder stock. LMAT, BDX pay a dividend while KRMD, ATRC, INFU do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.